We're delighted to share the publication of our Cochrane Review: Rituximab for myasthenia gravis
This systematic review examined the RCT evidence for this B cell depleting therapy in myasthenia, and is now available via the Cochrane Library.
🔗 https://t.co/sGEQzpzHxj
@andrew_behan Sorry to hear that Andrew. The team at MREH are experts in managing OMG and I'm sure will provide great care. I would speak to them about when they will be following you up.
During 2024, myaware has provided over £250,000 in grant funding to researchers and specialist nurses. Can you donate £10 so we can continue to support projects like this during our Specialist Nurses' Appeal 2024? https://t.co/MvAu92cipP
NEANU 2024
Friday 15th November, afternoon online session
*Five things about...
Headache
MS
Seizures
Neuromuscular disorders
The confused patient
Parkinsons
https://t.co/wcrTaOn7AH to book
Been a real treat to get started as @ABNTrainees' education and training representative with putting together this year's acute neurology boot camp! We have a fantastic line-up of expert consultant speakers.Register for free and join us on the 3rd of July:
https://t.co/VVaC6RCn1R
Important work here from the team @MCCN_UK@salfordco_nhs. This study of more than 1,600 people with multiple sclerosis shows ethnicity & deprivation negatively impact access to disease-modifying therapy for relapsing-remitting #MS
https://t.co/IWNrI4npix
Azathioprine is still an important medication in the management of MG. Liver function test rises are often transient and self limiting but we highlight how azathioprine metabolite testing can be used to help adjust the dose.